<DOC>
	<DOC>NCT00145327</DOC>
	<brief_summary>This extension study is designed to assess the long term safety and efficacy of zoledronic acid in postmenopausal women with osteoporosis who have participated in the CZOL446H2301 (NCT00049829): HORIZON Pivotal Fracture Trial. This extension study began after the 3-year core study ended. Baseline is the same as Year 3.</brief_summary>
	<brief_title>Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients who have received 3 infusions in the HORIZONPivotal Fracture (PFT) Study. Poor kidney, eye, or liver health Use of certain therapies for osteoporosis in the HORIZONPFT study (other than the study medication) Abnormal calcium levels in the blood Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>68 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Osteoporosis, Zoledronic Acid</keyword>
</DOC>